Table 3.
Reasons Patients Preferred Fremanezumab by Category of Prior Preventive Treatmenta,b
| Prior preventive treatmentc |
Antiepileptics N = 130 |
Antihypertensives N = 62 |
Tricyclic antidepressants N = 53 |
OnabotulinumtoxinA N = 28 |
SSRIs/SNRIs N = 27 |
|---|---|---|---|---|---|
| Reason for preventive treatment preference, n (%)d |
Preferred fremanezumab n = 119 (91.5%) |
Preferred fremanezumab n = 55 (88.7%) |
Preferred fremanezumab n = 49 (92.5%) |
Preferred fremanezumab n = 23 (82.1%) |
Preferred fremanezumab n = 26 (96.3%) |
| Reduces attack frequency | 100 (84.0) | 48 (87.3) | 40 (81.6) | 18 (78.3) | 20 (76.9) |
| Reduces migraine intensity | 89 (74.8) | 38 (69.1) | 38 (77.6) | 17 (73.9) | 17 (65.4) |
| Reduces attack duration | 81 (68.1) | 32 (58.2) | 32 (65.3) | 14 (60.9) | 15 (57.7) |
| Reduces migraine-associated symptoms | 71 (59.7) | 27 (49.1) | 30 (61.2) | 14 (60.9) | 15 (57.7) |
| Reduces migraine-associated disability | 74 (62.2) | 30 (54.5) | 27 (55.1) | 14 (60.9) | 16 (61.5) |
| Causes less side effects | 78 (65.5) | 22 (40.0) | 33 (67.3) | 8 (34.8) | 12 (46.2) |
| More convenient | 45 (37.8) | 23 (41.8) | 19 (38.8) | 8 (34.8) | 9 (34.6) |
| Other | 1 (0.8) | 0 | 0 | 2 (8.7) | 2 (7.7) |
SNRI serotonin-norepinephrine reuptake inhibitor, SSRI selective serotonin reuptake inhibitor
aPatients may have received prior preventive treatments in more than one class, and patients reported their preference for fremanezumab versus the prior treatment for each prior preventive treatment used. Thus, patients in the survey study sample may have reported preference for fremanezumab versus prior treatment for more than one class of treatment
bPatients responded to the following question for each preventive treatment that they reported having taken in the 5 years prior to the clinical trial: “Overall, which medicine did you prefer more, the injectable medicine you received as part of the clinical trial or (prior migraine preventive medication)?”
cPreferred prior preventive treatment: antiepileptics, 11 (8.5%); antihypertensives, 7 (11.3%); tricyclic antidepressants, 4 (7.5%); onabotulinumtoxinA, 5 (17.9%); SSRI/SNRI, 1 (3.7%)
dPercentages were calculated using the number reporting preference for fremanezumab as a denominator